Sandra Roy Receives Fellowship

Sandra Roy, Ph.D. candidate in animal biotechnology and biomedical sciences, has been a research fellow and lab manager in Margaret Riley’s laboratory since 2009, where she has studied bacteriocins, toxins that bacteria produce to attack other closely related bacteria, particularly those that are active against Gram negative strains. Riley, Roy and colleagues formed the company Bacteriotix in 2010 to investigate the use of bacteriocins as new drug candidates for treating these infections. The fellowship will allow Roy to expand her basic laboratory research on catheter-acquired urinary tract infection (CAUTI) interventions to include proof-of-concept studies on the most promising drug candidates. This will include purifying bacteriocins to the level required for a manufacturer to use them in a test batch for FDA-required safety and efficacy studies.Roy, Riley and colleagues have engaged Pheromonicin Biotech USA, Inc. to commercialize this product and the fellowship should accelerate the process.

Read the News & Media Relations article here.

Current News | News Archive